WO1998006423A1 - Composition comprising insulin and insulin-like growth factor-i (igf-i) - Google Patents
Composition comprising insulin and insulin-like growth factor-i (igf-i) Download PDFInfo
- Publication number
- WO1998006423A1 WO1998006423A1 PCT/US1997/013566 US9713566W WO9806423A1 WO 1998006423 A1 WO1998006423 A1 WO 1998006423A1 US 9713566 W US9713566 W US 9713566W WO 9806423 A1 WO9806423 A1 WO 9806423A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- igf
- insulin
- nph insulin
- nph
- composition
- Prior art date
Links
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 title claims abstract description 286
- 239000000203 mixture Substances 0.000 title claims abstract description 91
- 102100037852 Insulin-like growth factor I Human genes 0.000 title description 243
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title description 202
- 102000004877 Insulin Human genes 0.000 title description 126
- 108090001061 Insulin Proteins 0.000 title description 125
- 229940125396 insulin Drugs 0.000 title description 101
- LEMUFSYUPGXXCM-JNEQYSBXSA-N caninsulin Chemical compound [Zn].C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC3N=CN=C3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1C=NC=N1 LEMUFSYUPGXXCM-JNEQYSBXSA-N 0.000 claims abstract description 153
- 102000005237 Isophane Insulin Human genes 0.000 claims abstract description 141
- 108010081368 Isophane Insulin Proteins 0.000 claims abstract description 140
- 238000002347 injection Methods 0.000 claims abstract description 101
- 239000007924 injection Substances 0.000 claims abstract description 101
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims abstract description 51
- 238000009472 formulation Methods 0.000 claims abstract description 43
- 239000000872 buffer Substances 0.000 claims abstract description 34
- 239000003381 stabilizer Substances 0.000 claims abstract description 22
- 241000124008 Mammalia Species 0.000 claims abstract description 19
- 230000000065 osmolyte Effects 0.000 claims abstract description 11
- 230000003345 hyperglycaemic effect Effects 0.000 claims abstract description 6
- 125000000218 acetic acid group Chemical class C(C)(=O)* 0.000 claims abstract 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 38
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims description 36
- 238000000034 method Methods 0.000 claims description 36
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 22
- 239000011780 sodium chloride Substances 0.000 claims description 21
- 238000002156 mixing Methods 0.000 claims description 15
- 235000019445 benzyl alcohol Nutrition 0.000 claims description 12
- 150000001242 acetic acid derivatives Chemical class 0.000 claims description 11
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 10
- 239000001632 sodium acetate Substances 0.000 claims description 10
- 235000017281 sodium acetate Nutrition 0.000 claims description 10
- 239000008366 buffered solution Substances 0.000 claims description 7
- 239000003472 antidiabetic agent Substances 0.000 claims description 6
- 229940126904 hypoglycaemic agent Drugs 0.000 claims description 5
- 239000008351 acetate buffer Substances 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 73
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 61
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 10
- 239000003937 drug carrier Substances 0.000 abstract description 2
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 88
- 239000000902 placebo Substances 0.000 description 47
- 229940068196 placebo Drugs 0.000 description 47
- 108010090613 Human Regular Insulin Proteins 0.000 description 40
- 102000013266 Human Regular Insulin Human genes 0.000 description 40
- 229940103471 humulin Drugs 0.000 description 40
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 38
- 239000008103 glucose Substances 0.000 description 37
- 239000000243 solution Substances 0.000 description 31
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 30
- 230000000694 effects Effects 0.000 description 30
- 210000004369 blood Anatomy 0.000 description 28
- 239000008280 blood Substances 0.000 description 28
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 24
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 22
- 241000700159 Rattus Species 0.000 description 22
- 235000002639 sodium chloride Nutrition 0.000 description 22
- 239000000725 suspension Substances 0.000 description 22
- 230000002378 acidificating effect Effects 0.000 description 21
- 238000007920 subcutaneous administration Methods 0.000 description 21
- 230000002218 hypoglycaemic effect Effects 0.000 description 20
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 20
- 108010051696 Growth Hormone Proteins 0.000 description 19
- 102100038803 Somatotropin Human genes 0.000 description 19
- 239000000122 growth hormone Substances 0.000 description 19
- 230000002641 glycemic effect Effects 0.000 description 15
- 229940103453 novolin Drugs 0.000 description 15
- 208000013016 Hypoglycemia Diseases 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 13
- 101001055320 Myxine glutinosa Insulin-like growth factor Proteins 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 12
- 235000018102 proteins Nutrition 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 238000010521 absorption reaction Methods 0.000 description 10
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- -1 for example Substances 0.000 description 10
- 238000002560 therapeutic procedure Methods 0.000 description 10
- 208000035475 disorder Diseases 0.000 description 9
- 229920000136 polysorbate Polymers 0.000 description 9
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 9
- 206010022489 Insulin Resistance Diseases 0.000 description 8
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 8
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 8
- 230000008901 benefit Effects 0.000 description 8
- 230000007423 decrease Effects 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 238000001802 infusion Methods 0.000 description 8
- 230000003914 insulin secretion Effects 0.000 description 8
- 229960001052 streptozocin Drugs 0.000 description 8
- 239000004094 surface-active agent Substances 0.000 description 8
- 238000001990 intravenous administration Methods 0.000 description 7
- 229950008882 polysorbate Drugs 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 241000282412 Homo Species 0.000 description 6
- 108020004511 Recombinant DNA Proteins 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 239000013078 crystal Substances 0.000 description 6
- 239000010432 diamond Substances 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 102000044162 human IGF1 Human genes 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 230000002503 metabolic effect Effects 0.000 description 6
- 238000003127 radioimmunoassay Methods 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 5
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 5
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 5
- 102000013275 Somatomedins Human genes 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 235000012000 cholesterol Nutrition 0.000 description 5
- 229960002897 heparin Drugs 0.000 description 5
- 229920000669 heparin Polymers 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 229910017053 inorganic salt Inorganic materials 0.000 description 5
- 238000007912 intraperitoneal administration Methods 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 4
- 102000004375 Insulin-like growth factor-binding protein 1 Human genes 0.000 description 4
- 108090000957 Insulin-like growth factor-binding protein 1 Proteins 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 229920001213 Polysorbate 20 Polymers 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 230000005856 abnormality Effects 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000008512 biological response Effects 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 235000021152 breakfast Nutrition 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 238000001647 drug administration Methods 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 102000028416 insulin-like growth factor binding Human genes 0.000 description 4
- 108091022911 insulin-like growth factor binding Proteins 0.000 description 4
- 238000007726 management method Methods 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 229920001983 poloxamer Polymers 0.000 description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
- 239000001103 potassium chloride Substances 0.000 description 4
- 235000011164 potassium chloride Nutrition 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 239000001488 sodium phosphate Substances 0.000 description 4
- 229910000162 sodium phosphate Inorganic materials 0.000 description 4
- 235000011008 sodium phosphates Nutrition 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 150000005846 sugar alcohols Chemical class 0.000 description 4
- 238000013268 sustained release Methods 0.000 description 4
- 239000012730 sustained-release form Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 229940123208 Biguanide Drugs 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 241001631457 Cannula Species 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 3
- 108010014663 Glycated Hemoglobin A Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102000015779 HDL Lipoproteins Human genes 0.000 description 3
- 108010010234 HDL Lipoproteins Proteins 0.000 description 3
- 108010084048 Human Isophane Insulin Proteins 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 241001202975 Isophanes Species 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 229940100389 Sulfonylurea Drugs 0.000 description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 239000008228 bacteriostatic water for injection Substances 0.000 description 3
- 150000004283 biguanides Chemical class 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000000378 dietary effect Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000013401 experimental design Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 230000003204 osmotic effect Effects 0.000 description 3
- 210000000496 pancreas Anatomy 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 229960000502 poloxamer Drugs 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 229940068977 polysorbate 20 Drugs 0.000 description 3
- 238000002203 pretreatment Methods 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000008223 sterile water Substances 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- 229910052725 zinc Inorganic materials 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 201000005948 Donohue syndrome Diseases 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 101001044927 Homo sapiens Insulin-like growth factor-binding protein 3 Proteins 0.000 description 2
- 102000005561 Human Isophane Insulin Human genes 0.000 description 2
- 102000004372 Insulin-like growth factor binding protein 2 Human genes 0.000 description 2
- 108090000964 Insulin-like growth factor binding protein 2 Proteins 0.000 description 2
- 102100022708 Insulin-like growth factor-binding protein 3 Human genes 0.000 description 2
- 102000016261 Long-Acting Insulin Human genes 0.000 description 2
- 108010092217 Long-Acting Insulin Proteins 0.000 description 2
- 229940100066 Long-acting insulin Drugs 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 108010026951 Short-Acting Insulin Proteins 0.000 description 2
- 229940123958 Short-acting insulin Drugs 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 230000001195 anabolic effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 108091008324 binding proteins Proteins 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000007979 citrate buffer Substances 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 238000002481 ethanol extraction Methods 0.000 description 2
- 239000012537 formulation buffer Substances 0.000 description 2
- 230000010030 glucose lowering effect Effects 0.000 description 2
- 229960002989 glutamic acid Drugs 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 235000014304 histidine Nutrition 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 239000003978 infusion fluid Substances 0.000 description 2
- 239000004026 insulin derivative Substances 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000012931 lyophilized formulation Substances 0.000 description 2
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 229940068965 polysorbates Drugs 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000009256 replacement therapy Methods 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 206010042772 syncope Diseases 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- XMQUEQJCYRFIQS-YFKPBYRVSA-N (2s)-2-amino-5-ethoxy-5-oxopentanoic acid Chemical compound CCOC(=O)CC[C@H](N)C(O)=O XMQUEQJCYRFIQS-YFKPBYRVSA-N 0.000 description 1
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 239000004254 Ammonium phosphate Substances 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000272522 Anas Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 101001034686 Bos taurus Insulin-like growth factor I Proteins 0.000 description 1
- 108010075254 C-Peptide Proteins 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000736355 Euthyroides Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 238000000729 Fisher's exact test Methods 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 101000852815 Homo sapiens Insulin receptor Proteins 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 101150088952 IGF1 gene Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 206010022491 Insulin resistant diabetes Diseases 0.000 description 1
- 102000004371 Insulin-like growth factor binding protein 5 Human genes 0.000 description 1
- 108090000961 Insulin-like growth factor binding protein 5 Proteins 0.000 description 1
- 102000004369 Insulin-like growth factor-binding protein 4 Human genes 0.000 description 1
- 108090000969 Insulin-like growth factor-binding protein 4 Proteins 0.000 description 1
- 102000004883 Insulin-like growth factor-binding protein 6 Human genes 0.000 description 1
- 108090001014 Insulin-like growth factor-binding protein 6 Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- XUIIKFGFIJCVMT-LBPRGKRZSA-N L-thyroxine Chemical compound IC1=CC(C[C@H]([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-LBPRGKRZSA-N 0.000 description 1
- 208000035369 Leprechaunism Diseases 0.000 description 1
- 206010024604 Lipoatrophy Diseases 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 206010068871 Myotonic dystrophy Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 201000011032 Werner Syndrome Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 206010001584 alcohol abuse Diseases 0.000 description 1
- 208000025746 alcohol use disease Diseases 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 229910000148 ammonium phosphate Inorganic materials 0.000 description 1
- 235000019289 ammonium phosphates Nutrition 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 229940124325 anabolic agent Drugs 0.000 description 1
- 239000003263 anabolic agent Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 229940127003 anti-diabetic drug Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 229940064804 betadine Drugs 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000009223 counseling Methods 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000667 effect on insulin Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 230000001610 euglycemic effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002070 germicidal effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 230000014101 glucose homeostasis Effects 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 230000009546 growth abnormality Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 102000047882 human INSR Human genes 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 210000003100 hypothalamo-hypophyseal system Anatomy 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229950004152 insulin human Drugs 0.000 description 1
- 230000002608 insulinlike Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 229950008325 levothyroxine Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000012731 long-acting form Substances 0.000 description 1
- 208000018773 low birth weight Diseases 0.000 description 1
- 231100000533 low birth weight Toxicity 0.000 description 1
- 235000011147 magnesium chloride Nutrition 0.000 description 1
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 description 1
- 239000004137 magnesium phosphate Substances 0.000 description 1
- 229910000157 magnesium phosphate Inorganic materials 0.000 description 1
- 229960002261 magnesium phosphate Drugs 0.000 description 1
- 235000010994 magnesium phosphates Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000022001 negative regulation of insulin secretion Effects 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 230000000422 nocturnal effect Effects 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000003538 oral antidiabetic agent Substances 0.000 description 1
- 229940127209 oral hypoglycaemic agent Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N p-hydroxybenzoic acid methyl ester Natural products COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000009984 peri-natal effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 229940116406 poloxamer 184 Drugs 0.000 description 1
- 229940044519 poloxamer 188 Drugs 0.000 description 1
- 229920000724 poly(L-arginine) polymer Polymers 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 108010011110 polyarginine Proteins 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 1
- 229910052939 potassium sulfate Inorganic materials 0.000 description 1
- 235000011151 potassium sulphates Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 238000009597 pregnancy test Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 229940048914 protamine Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000002294 pubertal effect Effects 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000000580 secretagogue effect Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- SFVFIFLLYFPGHH-UHFFFAOYSA-M stearalkonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 SFVFIFLLYFPGHH-UHFFFAOYSA-M 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000008362 succinate buffer Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
Definitions
- This invention relates to formulations containing insulin-like growth factor-I (IGF-I) and insulin useful, for example, in a method of treating hyperglycemic disorders such as diabetes in patients Description of Related Art
- IGF-I insulin-like growth factor-I
- insulin useful for example, in a method of treating hyperglycemic disorders such as diabetes in patients Description of Related Art
- IGF-I is a 7649-dalton polypeptide with a pi of 8 4 (Rinderknecht and Humbel, Proc. Natl Acad Sci USA. 73 2365 ( 1976), Rinderknecht and Humbel, J Biol Chem . 253 2769 ( 1978) belonging to a family of somatomedms with insulin-like and mitogenic biological activities that modulate the action of growth hormone (GH) Van Wyk et al , Recent Proa Horm Res . 30 259 ( 1974), Binoux. Ann Endoc ⁇ nol . 41 157 ( 1980), Clemmons and Van Wvk.
- GH growth hormone
- IGF-1 naturally occurs in human body fluids, for example, blood and human cerebral spinal fluid Most tissues and especially the liver produce IGF-1 together with specific IGF-bmding proteins Like GH, IGF-I is a potent anabolic protein See Tanner et al , Acta Endoc ⁇ nol . 84 681 -696 ( 1977), Uthne et al , J Clin Endoc ⁇ nol Metab,. 39 548-554 (1974) See also Ross et al . Intensive Care Med . 19 Suppl 2 S54-57 ( 1993). which is a review of the role of insulin, growth hormone, and IGT-I as anabolic agents in the critically ill
- IGF-I insulin-like growth factor binding prote ⁇ n-3
- ALS acid-labile subunit
- IGF-I may be purified from natural sources, e . g , human serum (Rinderknecht and Humbel, J Biol Chem . supra), or made recombinantly (e g , EP 123,228 and 128,733)
- Various methods for formulating IGF-1 have been described These include, for example, EP 440,989, which discloses a method for preparing a dried composition of IGF-I, which comprises drying a solution containing IGF-I together with a strong acid, WO 91/18621 on formulating IGF-I in a citrate buffer at pH 6, US Pat No 5,374,620 on formulating IGF-I and GH in a growth-promoting composition, PCT/SE94/00010 on a stable solution containing IGF-I in a phosphate buffer in an amount of 50 m ol or less, giving a pH of 5 5 to 6 5, which is isotonic and suitable for in j ection, and WO 95/34318 on
- IGF-I has hypoglycemic effects in humans similar to insulin when administered by intravenous bolus injection, but also promotes positive nitrogen balance Underwood et al , Hormone Research. 24 166 ( 1 86) IGF-I is known to exert glucose-lowering effects in both normal (Guler et al , N Engl J Med.. 317 137-140 [ 1987]) and diabetic individuals (Schoenle et al., Diabetologia. _4: 675-679 [1991 ]; Zenobi et al., J. Clin.
- Type I or insulin-dependent diabetes mellitus is associated with abnormalities of insulin and
- RhIGF-I has the ability to improve insulin sensitivity For example.
- rhIGF-I (70 ⁇ g/kg bid) improved insulin sensitivity in non-diabetic, insulin-resistant patients with myotonic dystrophy Vlachopapadopoulou e. fl/ . J. Chn Endo. Metab . 12 3715-3723 (1995) Saad et al . Diabetologia.37 Abstract 40 (1994) reported dose-dependent improvements in insulin sensitivity in adults with obesity and impaired glucose tolerance following 15 days of rhIGF-I treatment (25 ⁇ g and 100 ⁇ g/kg bid) RhIGF-I also improved msulm sensitivity and glycemic control in some patients with severe type A insulin resistance (Schoenle et al , Diabetologia.
- insulin resistance has not been considered a prominent feature of type I diabetes, it is clearly present m some individuals and may be most clinically important during adolescence As GH has well known anti-insulin effects, the elevated GH levels during adolescence may mediate much of this insulin resistance Press et al., supra; Defeo et al, supra; Campbell et -./.. N. Eng. J. Med.. supra, Campbell et al, Metabolism. supra; Arias et al. , supra; Davidson et al. , supra.
- WO 94/16722 discloses a method of chronic modification of cell barrier properties by exposing a cell to a modification-effective amount of IGF-I for at least about seven days and a method of chronic amelioration or reversal of insulin resistance.
- IGF-I was used to treat type II diabetes patients in the clinic at a dose of 120-160 ⁇ g/kg twice daily, the side effects outweighed the benefit of the treatment. Jabri et al., Diabetes. 42: 369-374 (1994). See also Wilton, Acta Paediatr.. 383: 137-141 (1992) regarding side effects observed upon treatment of patients with IGF-I.
- US Pat. No. 4,988,675 describes treatment of type II diabetics with IGF-I
- US Pat. No. 5,466,670 describes treatment of type I diabetics with IGF-I
- WO 91/03253 reports use of IGF-I to treat severe insulin- resistant diabetics
- WO 96/01 124 describes use of IGF-I to prevent diabetes, delay clinical onset of diabetes, and provide a protective effect against diabetes.
- WO 96/01 125 published 18 January 1996 discloses the use of a combination of insulin and an IGF-1 in the manufacture of a medicament for counteracting a decrease in nitrogen balance and for counteracting a decrease in protein synthesis and which can be used for treatment of a protein catabolism due to glucocorticoid excess.
- U.S. Pat. No. 5,091 ,173 discloses a composition suitable for topical application to mammalian skin or hair comprising a cell-free supernatant from a culture of dermal papilla cells sufficient to increase hair growth comprising one or more members of the IGF family selected from IGF-I, IGF-II, and insulin.
- an injectable drug other than insulin to treat diabetes such as IGF-I
- IGF-I insulin to treat diabetes
- IGF-I insulin to treat diabetes
- Adding more injections, for IGF-I administration, to regimens that already require several injections per day of insulin is not practical.
- IGF-I and insulin it would be necessary to have the resulting formulation stable and well absorbed by the patient, as well as having long-acting insulin.
- a long-acting insulin regulated in a time- and target-tissue-dependent manner in response to changing demands of the metabolic environment is described by Lewitt et at. Endocrinology. 129: 2254-2265 (1991).
- NPH insulin long-acting neutral protamine hagedom insulin
- IGF-I insulin-like growth factor-I
- the present invention provides a parenteral composition
- IGF-I and NPH insulin in a pharmaceutically acceptable carrier.
- they are present in amounts of from or about 1 to 10 mg IGF-I and from or about 0.2 to 2 mg NPH insulin, preferably at pH from or about 5 to 8, more preferably from or about 5 to 6.
- the amounts of IGF-I and NPH insulin in the composition are from or about 1 to 10 mg/mL each.
- the carrier be an acetic acid salt buffer and a phosphate buffer, which carrier contains a sodium counter-ion and a stabilizer.
- the composition contain a surfactant, preferably a polysorbate or poloxamer.
- the invention provides a composition, preferably for parenteral use, and preferably sterile, comprising IGF-I and NPH insulin in an acetic acid salt buffer.
- the invention provides a composition, preferably for parenteral use, and preferably sterile, comprising IGF-I and NPH insulin in a weight ratio of NPH insulin to IGF-I of from or about 10: 1 to 1 :50 (w/w), from or about 0.05 to 0.3 M of an osmolyte, from or about 0.1 to 10 mg/mL of a stabilizer, from or about 1 to 5 mg/mL of a surfactant, and from or about 5 to 100 mM of a buffer at from or about pH 5 to 7, more preferably 5 to 6.
- the invention provides a method for treating a hyperglycemic disorder such as diabetes in a mammal comprising administering to the mammal, preferably by either injection or infusion an effective amount of one of the above compositions
- This invention provides a solution to the problem of dosing IGF-I It was an unexpected and fortuitous findmg that of the many formulations of insulin that are available, only one type, NPH insulin, could be mixed with IGF-I In addition, unexpected advantages of the dosing of the combmation of NPH insulin and IGF-I were discovered upon experimentation as described in detail below
- the present invention achieves the goal of being able to mix long-acting NPH insulin and IGF-I, contained in separate vials, in the same syringe, and to inject the mix immediately, and to use the same amount of insulin as is normally used, so that it will be most effective in lowering blood glucose
- Figure 1 A depicts an acidic pH reversed-phase chromatogram of HUMULIN® R brand insulin
- Figure I B depicts an acidic pH reversed-phase chromatogram of HUMULIN® N brand insulin
- Figure 1C depicts an acidic pH reversed-phase chromatogram of IGF-I
- Figure 2A depicts an acidic pH reversed-phase chromatogram of HUMULIN® N brand insulin plus
- IGF-I Figure 2B depicts an acidic pH reversed-phase chromatogram of NOVOLIN® N brand insulin plus IGF-I
- Figure 3A depicts an acidic pH reversed-phase chromatogram of HUMULIN® U brand insulin
- Figure 3B depicts an acidic pH reversed-phase chromatogram of HUMULIN® U brand insulin plus IGF-I
- Figure 4A depicts an acidic pH reversed-phase chromatogram of HUMULIN® L brand insulin without IGF-1
- Figure 4B depicts an acidic pH reversed-phase chromatogram of NOVOLIN® L brand insulin without IGF-I
- Figure 5 A depicts an acidic pH reversed-phase chromatogram of HUMULIN® L brand insulin with addition of IGF-I
- Figure 5B depicts an acidic pH reversed-phase chromatogram of NOVOLIN® L brand insulin with addition of IGF-1
- Figure 6 shows a comparison of rhIGF-I and NPH insulin subcutaneous (SC) injections in STZ diabetic rats, by depicting a graph of plasma glucose versus time for the control (open circles with solid line), rhIGF-I (open circles with dotted line), NPH insulin (open triangles), two separate injections of rhIGF-I and NPH msulm (open squares), and a single injection of rhIGF-1 and NPH insulin (open/solid squares)
- Figure 7 shows a comparison of separate and single injections of IGF-1 and NPH insulin SC in STZ diabetic rats, by depicting a graph of percent change in plasma glucose versus time for the control (open squares), two separate injections (open diamonds), and a single injection of IGF-I and NPH insulin (open circles)
- Figure 8 shows a comparison of separate and single injections of IGF-I and NPH insulin SC in STZ diabetic rats, by depicting a graph of plasma insulin versus time for the control (open squares), two separate injections (open diamonds), and a single injection of IGF-I and NPH insulin (open circles)
- Figure 9 shows a comparison of separate and single injections of IGF-I and NPH insulin SC in STZ diabetic rats, by depicting a graph of plasma IGF-I versus time for the excipient (open squares), two separate ⁇ nject ⁇ ons(open diamonds), and a single injection of IGF-I and NPH insulin (open circles)
- Figure 10 shows a comparison of various SC injections in STZ diabetic rats, by depicting blood glucose versus time for NPH insulin in water (open squares), NPH insulin in IGF-I placebo (open diamonds), a single injection of IGF-I and NPH insulin (open circles), and two separate injections of IGF-I and NPH insulin (open triangles).
- Figure 1 1 shows the effect of IGF-I placebo on blood insulin in STZ diabetic rats injected SC, by depicting plasma insulin versus time for NPH insulin in water (open squares) and NPH insulin in IGF-1 placebo (open diamonds).
- Figure 12 shows a comparison of various SC injections in STZ diabetic rats, by depicting plasma IGF- I versus time for NPH insulin in water (open squares), NPH insulin in IGF-I placebo (open diamonds), a single injection of IGF-I and NPH insulin (open circles), and two separate injections of IGF-1 and NPH insulin (open triangles).
- Figure 13 shows a clinical study design involving four weeks of outpatient diabetes counseling followed by four weeks of treatment of patients having IDDM with insulin and either rhIGF-1 or placebo. The study ended with a two-week period of wash-out.
- Figure 14 shows the average daily glycemic levels and regression curve for the study shown in Figure
- the spiked and smooth lines represent the average of the four daily glucose levels and the best-fit regression curve, respectively.
- the regression curve lines overlapping in the two groups during the pre- treatment period (day -30 to 0), separate during the treatment period (day 0 to 30), with a definite lowering of the regression line of the rhIGF-l-treated group vs. control.
- a multiplication factor of 0.05551 is employed for S.I. unit conversion.
- Figure 15 shows total IGF-I levels during the treatment period for the study outlined in Figure 13.
- the mean + SEM is illustrated.
- Figure 16 shows the free IGF-1 levels during the treatment period for the study outlined in Figure 13.
- mammal for purposes of treatment refers to any animal classified as a mammal, including humans, domestic, and farm animals, and zoo, sports, or pet animals, such as dogs, horses, cats, sheep, pigs, cows, etc.
- the preferred mammal herein is a human.
- non-adult refers to mammals that are from perinatal age (such as low-birth-weight infants) up to the age of puberty, the latter being those that have not yet reached full growth potential.
- IGF-I refers to insulin-like growth factor from any species, including bovine, ovine, porcine, equine, and preferably human, in native-sequence or in variant form, and from any source, whether natural, synthetic, or recombinant.
- Preferred herein for animal use is that form of IGF-I from the particular species being treated, such as porcine IGF-I to treat pigs, ovine IGF-I to treat sheep, bovine IGF-I to treat cattle, etc
- Preferred herein for human use is human native-sequence, mature IGF-I, more preferably without a N-terminal methionine, prepared, e g , by the process described in EP 230,869 published August 5, 1987, EP 128,733 published December 19, 1984, or EP 288.451 published October 26, 1988 More preferably, this native-sequence IGF-I is recombinantly produced and is available from Genentech. Inc , South San Francisco, CA for clinical investigations
- the preferred IGF-I variants are those described in US Pat Nos 5,077,276, 5,164,370, or 5,470,828, or in WO 87/01038, / e , those wherein at least the glutamic acid residue is absent at position 3 from the N- terminus of the mature molecule or those having a deletion of up to five ammo acids at the N-termmus
- the most preferred variant has the first three ammo acids from the N-terminus deleted (variously designated as brain IGF, tIGF-I, des(l-3)-IGF-l, or des-IGF-I)
- NPH insulin refers to neutral protamine hagedorn insulin, otherwise known as “isophane,” from any species, including bovine, ovine, porcine, equine, and preferably human, and from any source, whether natural, synthetic, or recombinant Preferred herein for animal use is that form of NPH insulin from the particular species being treated, such as human NPH msulm to treat humans Preferred NPH insulin for human use is NPH insulin sold commercially by Novo-Nordisk under the trademark INSULATARTM or by Eli-Lilly under the trademark HUMULIN NTM All NPH insulin drugs reported in Diabetes Mellitus - Theory and Practice, fourth edition, Harold Rifkm, MD, Ed (Elsevier, New York, 1990), Chapter 29, and U.S Pharmacist. 18 (Nov Suppl ) p 38-40 (1993) are suitable herein
- hyperglycemic disorders refers to all forms of diabetes, such as type I and type II diabetes, as well as hyperinsulinemia and hyperlipidemia, e g , obese subjects, and insulin-resistant diabetes, such as Mendenhall's Syndrome, Werner Syndrome, leprechaunism, hpoatrophic diabetes, and other lipoatrophies
- diabetes especially type I and type II diabetes
- Diabetes itself refers to a progressive disease of carbohydrate metabolism involving inadequate production or utilization of insulin and is characterized by hyperglycemia and glycosu ⁇ a
- the term “treating” refers to both therapeutic treatment and prophylactic or preventative measures Those in need of treatment include those already with the disorder as well as those prone to having the disorder or diagnosed with the disorder or those in which the disorder is to be prevented
- Consecutive treatment or administration refers to treatment on at least a daily basis without interruption in treatment by one or more days. Intermittent treatment or administration, or treatment or
- hypoglycemic agent refers to secretagogues, preferably oral agents, excludmg msulm, which cause the secretion of msulm by the pancreas
- oral agents excludmg msulm
- More preferred herein for human use are the sulfonyiurea class of oral hypoglycemic agents Examples clude glybunde, g pizide, and g clazide
- agents that enhance msulm sensitivity such as biguanides, are withm this definition, and also are preferred B. Modes for Carrying Out the Invention
- the IGF-I and NPH insulin are combined and directly administered to the mammal by any suitable technique, including infusion and injection.
- the specific route of administration will depend, e.g., on the medical history of the patient, including any perceived or anticipated side effects using NPH insulin or IGF-I alone, and the particular disorder to be corrected.
- parenteral administration include subcutaneous, intramuscular, intravenous, intraarterial, and intraperitoneal administration.
- the administration is by continuous infusion (using, e.g., slow-release devices or minipumps such as osmotic pumps or skin patches), or by injection (using, e.g., intravenous or subcutaneous means).
- the administration is subcutaneous injection for the mixture.
- the administration may also be as a single bolus or by slow-release depot formulation. Delivery of NPH insulin and IGF-I by injection will be the preferred form of administration for treating diabetes.
- the IGF-I and NPH insulin composition to be used in the therapy will be formulated and dosed in a fashion consistent with good medical practice, taking into account the clinical condition of the individual patient (especially the side effects of treatment with NPH insulin or IGF-I alone), the site of delivery of the IGF-1 and NPH insulin composition, the method of administration, the scheduling of administration, and other factors known to practitioners.
- the "effective amounts" of each component for purposes herein are thus determined by such considerations and must be amounts that result in bioavailability of the drugs to the mammal and blood glucose lowering effect.
- the total pharmaceutically effective amount of the IGF-I and NPH insulin administered parenterally per dose will be in the range of from or about 10 ⁇ g/kg/day to 200 ⁇ g/kg/day of IGF- I based on kg of patient body weight, and from or about 0.5 to 500 units/day of NPH insulin, although, as noted above, this will be subject to a great deal of therapeutic discretion.
- the dose of IGF-I is from or about 1 to 10 mg twice per day, more preferably from or about 20 to 80 ⁇ g/kg/injection (i.e., from or about 1.5 to 6 mg) twice a day subcutaneously, and the dose of NPH insulin is from or about 5 to 50 units/injection (i.e., from or about 0.2 to 2 mg) twice a day subcutaneously.
- the ratio of NPH insulin to IGF-I in this formulation by weight is generally from or about 10: 1 to 1 :50, preferably from or about 1 : 1 to 1 :20, more preferably from or about 1 : 1 to 1 : 10, still more preferably, from or about 1 : 1 to 1 :5, and most preferably from or about 1 : 1 to 1 :3.
- an infusion device may also be employed for continuous SC infusions.
- An intravenous bag solution may also be employed.
- the key factor in selecting an appropriate dose is the result obtained, as measured by decreases in blood glucose so as to approximate the normal range, or by other criteria for measuring treatment of diabetes as defined herein as are deemed appropriate by the practitioner. Further information on dosing NPH insulin can be found in Diabetes Mellitus - Theory and Practice, supra,
- the insulin administration is continuous and the IGF-I is administered to the mammal in an intermittent fashion so as to sustain its biological response in the treatment of diabetes.
- This is accomplished usually by administering a therapeutically effective amount of the IGF-I to the mammal to provide an exposure to IGF-I and NPH insulin for a period of time that provides the maximum biological response in the mammal, then discontinuing the administration of the IGF-I (but not the NPH insulin) for a period of time equal to or less than the time period during which the IGF-I was previously administered, then administering a therapeutically effective amount of IGF-I (with NPH insulin administration continuing) to the mammal to provide an exposure to IGF-I and NPH insulin for a period of tune that provides the maximum biological response in the mammal, then discontinuing the administration of the IGF-I (but not the NPH insulin) for a period of time equal to or less than the time period during which the IGF-
- the formulation herein is suitably administered along with an IGF binding protein, for example, one of those currently known, e , IGFBP- 1 , IGFBP-2, IGFBP-3, IGFBP-4, IGFBP-5, or IGFBP-6, or with the ALS of the IGF binding complex
- IGF binding protein for example, one of those currently known, e , IGFBP- 1 , IGFBP-2, IGFBP-3, IGFBP-4, IGFBP-5, or IGFBP-6, or with the ALS of the IGF binding complex
- IGF-I may also be coupled to a receptor or antibody or antibody fragment for administration
- the preferred binding protein for IGF-I herein is IGFBP3, which is described in U S Pat No 5,258,287 and by Martin and Baxter, J. Biol Chem..
- This glycosylated IGFBP3 protein is an acid-stable component of about 53 Kd on a non-reducing SDS-PAGE gel of a 125- 150 Kd glycoprotein complex found in human plasma that carries most of the endogenous IGFs and is also regulated by GH
- the administration of the IGF binding protein with IGF-1 and NPH insulin may be accomplished by the method described in U S Pat No 5,187,151 Briefly, the IGT-1 and IGFBP are administered in effective amounts by subcutaneous bolus injection in a molar ratio of from or about 0 5 1 to 3 1 , preferably about I 1 , the NPH insulin is already present with the IGF-I
- the formulation is suitably administered along with an effective amount of a hypoglycemic agent such as a sulfonylurea
- a hypoglycemic agent such as a sulfonylurea
- the hypoglycemic agent is administered to the mammal by any suitable technique including parenterally, intranasally, orally, or b any other effective route Most preferably, the administration is by the oral route
- MICRONASETM Tablets glybu ⁇ de
- marketed by Upjohn in 1 25, 2 5, and 5 mg tablet concentrations are suitable for oral administration
- the usual maintenance dose for Type II diabetics, placed on this therapy is generally in the range of from or about 1 25 to 20 mg per day, which may be given as a single dose or divided throughout the day as deemed appropriate fPhvsician's Desk Reference.
- glybu ⁇ de-based tablets available for prescription include GLYNASETM brand drug (Upjohn) and DIABETATM brand drug (Hoechst-Roussel) GLUCOTROLTM (Pratt) i s the trademark for a ghpizide (l -cyclohexyl-3-[p-[2-(5-methylpyraz ⁇ ne carboxam ⁇ de)ethyl]phenyl]sulfonyl]urea) tablet available in both 5 and 10 mg strengths and is also prescribed to Type II diabetics who require hypoglycemic therapy following dietary control or in patients who have ceased to respond to other sulfonylureas [Physician's Desk Reference.
- hypoglycemic agents such as the biguanides (e g , metformm and phenformm) or troglitozones, or other drugs affecting insulin action may also be employed.
- biguanides e g , metformm and phenformm
- troglitozones or other drugs affecting insulin action
- sustained-release compositions include semi-permeable polymer matrices in the form of shaped articles, e g , films, or microcapsules
- sustained-release matrices include polylactides (U S Pat No 3,773,919, EP 58,481), copolymers of L-glutamic acid and gamma-ethyl-L-glutamate (Sidman et al , Biopolvmers. 22, 547-556 [1983]), poly(2-hydroxyethyl methacrylate) (Langer et al, J. Biomed, Mater. Res..
- Sustained-release IGF-I compositions also include liposomally entrapped IGF-I. Liposomes containing IGF-I are prepared by methods known per se: DE 3,218,121 ; Epstein et al, Proc. Natl. Acad. Sci. U.S.A.. 82: 3688-3692 (1985); Hwang et al, Proc. Natl. Acad. Sci. U.S.A..
- the liposomes are of the small (from or about 200 to 800 Angstroms) unilamellar type in which the lipid content is greater than about 30 mol. percent cholesterol, the selected proportion being adjusted for the optimal IGF-I and NPH insulin therapy.
- the IGF-I and NPH insulin are formulated generally by mixing each at the desired degree of purity, in a unit dosage injectable form (solution, suspension, or emulsion), with a pharmaceutically, or parenterally, acceptable carrier, i.e., one that is non-toxic to recipients at the dosages and concentrations employed and is compatible with other ingredients of the formulation.
- a pharmaceutically, or parenterally, acceptable carrier i.e., one that is non-toxic to recipients at the dosages and concentrations employed and is compatible with other ingredients of the formulation.
- the formulation preferably does not include oxidizing agents and other compounds that are known to be deleterious to polypeptides.
- the formulations are prepared by contacting the IGF-I and NPH insulin each uniformly and intimately with liquid carriers or finely divided solid carriers or both. Then, if necessary, the product is shaped into the desired formulation.
- the carrier is a parenteral carrier, more preferably a solution that is isotonic with the blood of the recipient. Examples of such carrier vehicles include water, saline, Ringer's solution, a buffered solution, and dextrose solution. Non-aqueous vehicles such as fixed oils and ethyl oleate are also useful herein.
- the carrier suitably contains minor amounts of additives such as substances that enhance isotonicity and chemical stability.
- additives such as substances that enhance isotonicity and chemical stability.
- Such materials are non-toxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, succinate, acetic acid, and other organic acids or their salts; antioxidants such as ascorbic acid; low molecular weight (less than about ten residues) polypeptides, e.g., polyarginine or tripeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; glycine; amino acids such as glutamic acid, aspartic acid, histidine, or arginine; monosaccharides, disaccharides, and other carbohydrates including cellulose or its derivatives, glucose, mannose, trehalose, or dextrins; chelating agents such as EDTA; sugar alcohols such as
- the IGF-1 and NPH insulin are typically formulated in such vehicles at a pH of from or about 4.5 to 8.
- Full-length IGF-I is generally stable at a pH of no more than about 6.5; des(l-3)-IGF-I is stable at from or about 3.2 to 5. It will be understood that use of certain of the foregoing excipients, carriers, or stabilizers will result in the formation of IGF-I or insulin salts.
- the final preparation may be a stable liquid or lyophiiized solid.
- the composition comprises IGF-I and NPH insulin in a weight ratio of NPH insulin:IGF-I of from or about 10: 1 to 1 :50 (w/w), from or about 0.05 to 0.3 M of an osmolyte, preferably an inorganic salt and/or sugar alcohol, from or about 0.1 to 10 mg/mL of at least one stabilizer, from or about 1 to 5 mg/mL of a surfactant, and from or about 5 to 100 mM of a buffer at from or about pH 5 to 7, preferably 5 to 6.
- the more preferred amounts of IGF-I and NPH insulin in this composition are from or about 1 to 10 mg IGF-I and from or about 0.2 to 2 mg NPH insulin in each injection.
- the more preferred weight ratio of NPH insu!in:IGF-I is from or about 1 : 1 to 1 :20, more preferably from or about 1 : 1 to 1 : 10, still more preferably from or about 1 : 1 to 1 :5, and most preferably from or about 1 : 1 to 1 :3.
- Osmolyte refers to an isotonic modifier or osmotic adjuster that lends osmolality to the buffered solution. Osmolality refers to the total osmotic activity contributed by ions and non-ionized molecules to a solution. Examples include inorganic salts such as sodium chloride and potassium chloride, mannitol, PEG, polypropylene glycol, glycine, sucrose, trehalose, glycerol, amino acids, and sugar alcohols such as mannitol known to the art that are generally regarded as safe (GRAS). The preferred osmolyte herein is sodium chloride or potassium chloride.
- the "stabilizer” is any compound that functions to preserve the active ingredients in the formulation, i.e., NPH insulin and IGF-1, so that they do not degrade or otherwise become inactive over a reasonable period of time or develop pathogens or toxins that prevent their use.
- stabilizers include preservatives that prevent bacteria, viruses, and fungi from proliferating in the formulation, anti-oxidants, or other compounds that function in various ways to preserve the stability of the formulation.
- quaternary ammonium salts are useful stabilizers in which the molecular structure includes a central nitrogen atom joined to four organic (usually alkyl or aryl) groups and a negatively charged acid radical.
- These salts are useful as surface-active germicides for many pathogenic non-sporulating bacteria and fungi and as stabilizers. Examples include octadecyldimethylbenzyl ammonium chloride, hexamethoniu chloride, benzalkonium chloride (a mixture of alkylbenzyldimethylammonium chlorides in which the alkyl groups are long-chain compounds), and benzethonium chloride.
- stabilizers include aromatic alcohols such as phenol and benzyl alcohol, alkyl parabens such as methyl or propyl paraben, and m-cresol.
- aromatic alcohols such as phenol and benzyl alcohol
- alkyl parabens such as methyl or propyl paraben
- m-cresol m-cresol.
- the most preferred stabilizer herein is phenol or benzyl alcohol.
- the stabilizer is included in a stable liquid form of the NPH insulin and IGF-I formulation, but not in a lyophilized form of the formulation. In the latter case, the stabilizer is present in the bacteriostatic water for injection (BWF1) used for reconstitution.
- BWF1 bacteriostatic water for injection
- the surfactant is also optionally present in the reconstitution diluent.
- the "inorganic salt” is a salt that does not have a hydrocarbon-based cation or anion.
- Examples include sodium chloride, ammonium chloride, potassium chloride, magnesium chloride, calcium chloride, sodium phosphate, calcium phosphate, magnesium phosphate, potassium phosphate, ammonium phosphate, sodium sulfate, ammonium sulfate, potassium sulfate, magnesium sulfate, calcium sulfate, etc.
- the cation is sodium and the anion is chloride or sulfate, and the most preferred inorganic salt is potassium chloride or sodium chloride.
- the "surfactant” acts to increase the solubility of the IGF-1 and NPH insulin at a pH from or about 4 to 7. It is preferably a nonionic surfactant such as a polysorbate, e.g., polysorbates 20, 60, or 80, a poloxamer, e.g., poloxamer 184 or 188, or any others known to the art that are GRAS. More preferably, the surfactant is a polysorbate or poloxamer, more preferably a polysorbate, and most preferably polysorbate 20.
- a nonionic surfactant such as a polysorbate, e.g., polysorbates 20, 60, or 80, a poloxamer, e.g., poloxamer 184 or 188, or any others known to the art that are GRAS. More preferably, the surfactant is a polysorbate or poloxamer, more preferably a polysorbate, and most preferably polysorbate 20.
- the "buffer” may be any suitable buffer that is GRAS and generally confers a pH from or about 4.8 to 8, preferably from or about 5 to 7, more preferably from or about 5 to 6, on the NPH insulin + IGF-I formulation, and preferably a pH of from or about 5 to 6, more preferably from or about 5 to 5.5, on the IGF-I formulation.
- suitable buffer that is GRAS and generally confers a pH from or about 4.8 to 8, preferably from or about 5 to 7, more preferably from or about 5 to 6, on the NPH insulin + IGF-I formulation, and preferably a pH of from or about 5 to 6, more preferably from or about 5 to 5.5, on the IGF-I formulation.
- acetic acid salt buffer which is any salt of acetic acid, including sodium acetate and potassium acetate
- succinate buffer phosphate buffer, citrate buffer, histidine buffer, or any others known to the art to have the desired effect.
- the most preferred buffer is sodium acetate, optionally in combination with sodium phosphate.
- composition containing both IGF-I and NPH insulin is the following: a weight ratio of NPH insulin:IGF-I of from or about 1 : 1 to 1 :3, from or about 5 to 7 mg/mL of sodium chloride, from or about O.l to 3 mg/mL of phenol and/or from or about 6 to 10 mg/mL of benzyl alcohol, from or about I to
- the final formulation if a liquid, is preferably stored at a temperature of from or about 2 to 8° C for up to about four weeks.
- the formulation can be lyophilized and provided as a powder for reconstitution with water for injection that is stored as described for the liquid formulation.
- IGF-I and NPH insulin to be used for therapeutic administration must be sterile. Sterility is readily accomplished by filtration through sterile filtration membranes (e.g., 0.2 micron membranes).
- Therapeutic IGF-I and NPH insulin compositions generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle.
- IGF-1 and NPH insulin ordinarily will be stored in unit or multi-dose containers, for example, sealed ampules or vials, as an aqueous solution or as a lyophilized formulation for reconstitution.
- a lyophilized formulation 10-mL vials are filled with 5 mL of sterile-filtered 1% (w/v) aqueous NPH insulin solution, and the resulting mixture is lyophilized.
- the infusion solution is prepared by reconstituting the lyophilized NPH insulin using bacteriostatic Water-for-Injection. This infusion solution is then mixed with a similarly reconstituted IGF-I solution or a liquid IGF-I solution.
- the formulation containing both the IGF-I and NPH insulin can be made by many different methods.
- One method comprises mixing NPH insulin with an IGF-l-containing composition (having osmolyte, stabilizer, and buffer as described below).
- the IGF-I-containing solution useful for administering IGF-1 separately from NPH insulin and for admixing with the NPH insulin solution as described above is as follows: from or about 2 to 20 mg/mL of IGF- I, from or about 2 to 50 mg/mL of an osmolyte, from or about 1 to 15 mg/mL of at least one stabilizer, and a buffer (preferably an acetic acid salt buffer, and most preferably sodium acetate) in an amount such that the composition has a pH of from or about 5 to 5.5.
- a buffer preferably an acetic acid salt buffer, and most preferably sodium acetate
- the formulation may also contain a surfactant selected from the types described above, preferably in an amount of from or about 1 to 5 mg/mL, more preferably from or about 1 to 3 mg/mL.
- the osmolyte is an inorganic salt at a concentration of from or about 2 to 10 mg/mL or a sugar alcohol at a concentration of from or about 40 to 50 mg/mL
- the stabilizer is benzyl alcohol, phenol, or both
- the buffered solution is an acetic acid salt buffered solution. More preferably, the osmolyte is an inorganic salt, most preferably sodium chloride.
- the amount of IGF-I is from or about 8 to 12 mg/mL
- the amount of sodium chloride is from or about 5 to 6 mg/mL
- the stabilizers are benzyl alcohol in an amount of from or about 8 to 10 mg/mL and or phenol in an amount of from or about 2 to 3 mg/mL
- the buffer is about 50 mM sodium acetate so that the pH is about 5.4.
- the preferred amount of NPH insulin is about 100 units/mL, or about 4 mg/mL.
- the volumes of drugs can be varied or the concentration of NPH insulin can be fixed.
- the formulation contains polysorbate as a surfactant in an amount of from or about 1 to 3 mg/mL.
- a 50-mM acetate concentration in the starting IGF-1 solution before mixing with NPH insulin ensures that the final pH will not vary significantly from 5.4 in the final IGF-I/NPH insulin mixture to maintain high solubility of IGF-1 and low solubility of NPH insulin as a suspension over a wide mixing ratio range.
- a broader pH range in terms of stability of both proteins is from or about 4.5 to 8.
- Kits are also contemplated for this invention.
- a typical kit would comprise a container, preferably a vial, for the IGF-I formulation comprising IGF-1 in a pharmaceutically acceptable acetic acid salt buffer; a container, preferably a vial, comprising pharmaceutically acceptable NPH insulin, and instructions, such as a product insert or label, directing the user to combine the contents of the two containers, i.e., the two formulations, to provide a pharmaceutical formulation.
- the pharmaceutical formulation is for treating diabetes.
- the container with IGF-I additionally comprises sodium chloride and benzyl alcohol or phenol, or both, in the buffer at a pH of from or about 5.0 to 5.5.
- the user will be instructed to combine the contents of the containers, i.e., the two formulations, in a syringe for immediate injection.
- the container with IGF-I comprises from or about 8 to 12 mg mL of IGF-I, from or about 5 to 6 mg/mL of sodium chloride, from or about 8 to 10 mg/mL of benzyl alcohol or from or about 2 to 3 mg/mL of phenol, or both from or about 8 to 1 mg/mL of benzyl alcohol and from or about 2 to 3 mg/mL of phenol, in an about 50 mM sodium acetate buffered solution at a pH of about 5.4. More preferably, this container further comprises from or about 1 to 3 mg/mL polysorbate.
- IGF-I 10.0 mg/mL Sodium chloride 5.84 mg/mL Sodium acetate 50 mM, pH 5.4
- HUMULIN® R regular insulin human injection, USP, recombinant DNA origin
- HUMULIN® N NPH human insulin, recombinant DNA origin, isophane suspension
- NOVOLIN® N NPH human insulin, recombinant DNA origin, isophane suspension
- HUMULIN® L (Lente human insulin, recombinant DNA origin, zinc suspension)
- NOVOLIN® L (Lente human insulin, recombinant DNA origin, zinc suspension)
- HUMULIN® U (Ultralente, human insulin, recombinant DNA origin, extended zinc suspension) METHODS:
- the centrifuge step was designed to remove human insulin suspension from solution. After centrifugation, the insulin sample was filtered through a 0.22 ⁇ m filter to further remove human insulin suspension. After filtration the solution was analyzed by using the acidic pH reversed-phase HPLC method described below: solvent A: 0.1 % trifluoroacetic acid solvent B: 0.1% trifluoroacetic acid in acetonitrile flow rate: 0.5 mL/minute column temperature: 50° C wavelength: 214 nm injection volume: 25 ⁇ g/injection column: VYDAC® C18 HPLC column, 4.6 X 250 cm, 300 A
- IGF-I was diluted to 1 mg/mL using IGF-I placebo.
- the diluted sample was analyzed by the above HPLC method.
- Human insulin was mixed with IGF-I in an insulin syringe using the mixing method described above. Immediately after mixing, the mixture was injected into a centrifuge tube, then gently vortexed for 1 -2 seconds. After vortexing the mixture was centriftiged at 3000 r.p.m. for 10 minutes, then filtered through a 0.22 ⁇ m filter to remove human insulin suspension. The filtered sample was then analyzed by the acidic pH reversed phase HPLC method described above.
- Fig. 1 A shows that on acidic pH reversed-phase chromatogram of HUMULIN® R, human insulin elutes at 41 minutes.
- Fig. IB which is an acidic pH reversed-phase chromatogram of HUMULIN® N, shows that no human insulin was present in the solution. Human insulin in HUMULIN® N is present only as insoluble crystals. These crystals were removed by centrifugation and filtration.
- Fig. IC which is an acidic pH reversed-phase chromatogram of IGF-I in the formulation indicated below in Example II, shows that approximately 99% of IGF-I is intact and unoxidized and elutes at 22 minutes.
- Figures 2A and 2B represent acidic pH reversed-phase chromatograms of HUMULIN® N and
- NOVOLIN® N NOVOLIN® N, respectively, combined with IGF-I. After addition of IGF-1, human insulin remains crystalline.
- Figure 3A is an acidic pH reversed-phase chromatogram of HUMULIN® U. Since human insulin was present as crystals, human insulin was not detected in the solution by reversed-phase chromatography.
- Figure 3B shows an acidic pH reversed-phase chromatogram of HUMULIN® U plus IGF-I. After addition of IGF-1, approximately 0.7% of total human insulin was released from the HUMULIN® U crystals. The peak shape of IGF-I has been slightly altered; however, the peak area of IGF-I was not affected.
- HUMULIN® L is 30% amorphous and 70% crystalline human insulin. The size and shape of amorphous or crystalline human insulin appeared to be unchanged with the addition of IGF-I.
- Figures 4A and 4B show respectively the acidic pH reversed-phase chromatograms of HUMULIN® L and NOVOLIN® L without IGF-I. Human insulin presented as insoluble amorphous or crystalline form; therefore, it was removed by centrifugation and filtration. No human insulin was detected.
- Figures 5A and 5B show respectively the acidic pH reversed-phase chromatograms of HUMULIN® L and NOVOLIN® L with addition of IGF-I. After addition of IGF-I, approximately 4.8% of total human insulin was released into the solution. The peak area of IGF-I remained unchanged; however, the peak shape was slightly altered.
- the right jugular vein was then isolated through a small SC incision and cannulated using a 0.02 inch x 0.037 inch beveled silicon rubber-tipped cannula.
- Cannulas were flushed and checked for patency using heparin (10 U/mL) before closing wounds using 4-0 silk suture thread.
- Cannulas were "heparin locked" using -50 ⁇ heparin (100 U/mL) just before the animals were placed on a heated pad for recovery. Rats were placed in their vivarium cage when ambulatory.
- the cannulas were flushed daily with fresh heparin/saline to maintain patency.
- Two days after cannulation Study 1 (see below) was performed and two days later.
- Study 2 For these studies an extension tube of 12 inches of PE40 polyethylene tubing filled with heparin/saline was attached to the cannula after withdrawing the pin plugging the cannula. This line was connected to a syringe and left attached to the animal throughout the experiment. After each blood sample an equal volume of saline was re-injected via the cannula to maintain blood volume. Blood was sampled at the following times: at - 10 minutes, at 0 minutes, then the solutions shown below were injected, then blood was sampled again after 10, 20, 40, 60 minutes, 2, 3, 4, 6 hours.
- NPH insulin 5U from 100 U/mL stock
- the experimental design was as follows: Group Concentration fiiLUSCl rhIGF-1 placebo (pH 5.4 acetic acid) 50 rhIGF-I + NPH insulin two separate injections 100 x 2 3 rhIGF-I + NPH insulin single injection 100
- rhIGF-I (Genentech Inc, lot #G1 17AZ/A9841 AX) 10 mg/mL diluted 1 2 with IGF-I placebo
- the rhIGF-I consists of 10 mg mL IGF-I, 5 84 mg mL NaCl, 9 0 mg mL benzyl alcohol, 2 0 mg/mL polysorbate 20, 50 M sodium acetate, pH 5 4
- the intended final product configuration contains 7 mL (70 mg) of the above solution in a 10-mL glass vial, which is generally stored refrigerated (2-8° C) to maximize its lifetime
- This product is designed to be a ready-to-use liquid for subcutaneous or intravenous administration using a conventional needle and syringe 2)
- IGF-I placebo sodium acetate buffer at pH 5 4)
- Plasma glucose concentrations were measured using a Chem 1 A serum chemistry analyzer (Miles Laboratories, Tarrytown, NY) Insulin in plasma was measured by rat-specific radioimmunoassay (RI A) (Linco Research lnc , St Charles, MO ) Plasma IGF-I was measured by RIA after acid-ethanol extraction of the samples RESULTS Study 1
- the diabetic state of the rats is shown ( Figure 6) by the blood glucose levels (400 mg/100 L) in the animals Compared to the control group, which was injected with excipient, all treatments caused a significant fall in plasma glucose levels There was a clear difference between the groups in the initial glucose response
- the single-injection combination group (treated with IGF-I + NPH insulin) had a substantially lower plasma glucose level 10 and 20 mm after injection than all the other groups Twenty minutes post-mjection the blood glucose levels were Placebo 409 5 ⁇ 66 5.
- the single-injection group substantially decreased plasma glucose levels even after only 10 minutes (placebo 380 ⁇ 21 3, two separate injections 388 ⁇ 13 3; single injection 332 ⁇ 14 8 mg % ) and 20 minutes after the injection (placebo 445 3 ⁇ 17 6, two separate injections 275 4 ⁇ 25 3, single injection 216 8 ⁇ 19 5 mg %)
- This decrease was also noted on a relative percent change basis Therefore, it did not appear that the injection volume or the concentration were the cause of the difference between the separate-injection and the single-injection groups Insulin and IGF-I Levels in Blood
- the insulin and the IGF-I concentrations in blood were measured
- Figure 8 shows that there was a significant treatment effect on plasma msulm At forty minutes post- dosing the single- injection combination increased plasma insulin almost two-fold compared to the separate- injection group (placebo 1 15 ⁇ 45, two separate injections 63 0 ⁇ 12 2 single injection 1 12 8 ⁇ 21 0 ng/mL, p ⁇ 0 05 vs two separate injections)
- Figure 9 shows the serum IGF-I concentrations after the co- delivery of IGF-1 and NPH insulin, or after their separate injection Serum IGF-I concentrations were significantly higher in the single-injection combination treatment group than in the separate-injection group at 20 post-injection Therefore, the co-formulation of NPH insulin and IGF-I gave greater efficacy than if the formulations were injected separately and this increased efficacy was associated with a more rapid appearance of insulin in the blood and possibly of IGF-I in the blood Study 1 and 2 Combined Glucose Data
- NPH insulin is a relatively long-acting form of insulin that is usually given in the evening to maintain insulin concentrations overnight. Before the evening meal it is usual in addition to give an injection of a short- acting insulin.
- the current invention discloses an advantage in that a rapid release of a portion of the insulin occurs if NPH insulin is given with IGF-I. Therefore, for example, instead of a diabetic patient being given two injections, NPH insulin at bedtime and regular insulin before dinner, the current invention allows one injection of IGF-I/NPH insulin to be given before dinner. A reduction of the number of injections is therefore achieved.
- HbA glycosylated hemoglobin
- the study design included a 4-week lead-in period, a 4-week treatment period, and a 2-week wash-out period (Fig 13) Throughout the study the patients continued to receive two injections of regular and NPH insulm daily At study entry the patients were provided with detailed mstructions on home blood glucose (BG) monitoring technique They were instructed to test BG before breakfast, lunch, dinner, and the evening snack as well as any times of symptomatic hypoglycemia
- the glucose values were automatically stored in the meter (One Touch II - Lifescan Inc , Milpitas, CA) and electronically transferred to a personal computer at the study site during each clinic visit Dur g the lead-m period the patients were counseled weekly on general diabetes care and dietary management (day -28 and - 14 at the clinic, day -21 and -7 over the phone) Durmg this period the patients were provided with specific goals of glycemic control and were instructed to call the study sites as often as needed for assistance with sulm adjustment
- the patients were randomized to administer either rhIGF-I or placebo as an additional injection immediately before their morning msulm injections
- Patients were allocated using an adaptive randomization procedure that stratified based on Tanner stage and the glycosylated hemoglobin value on day -28 of the lead-in period
- a seven-day window penod was allowed between day - 1 of the lead-m period and day 1 of the treatment period
- the subjects were admitted to the hospital the afternoon preceding day 1 of treatment and received their usual msulin dose and diet
- an IV cannula was inserted into the distal forearm or antecubital fossa
- a s gle dose of rhIGF-I (80 ⁇ g/kg) or placebo was administered SC, followed by a SC insulin injection and breakfast
- the dosing of IGF-I in the morning was for safety reasons
- the a m regular insulin dose was reduced by 1/3 in both groups as a precaution against the development of hypoglycemia Blood samples were obtained for
- the rhIGF-I and placebo doses remained constant (80 ⁇ g/kg SC q a.m.).
- the insulin doses were adjusted in an attempt to achieve the following BG targets: fasting blood glucose (FBG) 80-120 mg/dl (4.4-6.7 mmol/L) for age greater than 12 years and 80-140 mg/dL (4.4-7.8 mmol/L) for age lower than 12 years; 80-180 mg/dL (4.4-10.0 mmol/L) at any other time.
- FBG fasting blood glucose
- 80-120 mg/dl 4.4-6.7 mmol/L
- 80-140 mg/dL 4.4-7.8 mmol/L
- 80-180 mg/dL 4.4-10.0 mmol/L
- Table II summarizes the laboratory evaluations carried out during the study.
- the primary indices of glycemic control were: 1) HbA, was measured at day -28 of the lead-in, as well as at days 1 and 28 of the treatment; 2) the average of the four daily home glucose monitoring values over the last ten days of the lead-in period was compared to the last ten days of treatment.
- the glycosylated hemoglobin was assayed by affinity chromatography (SmithKline Beecham Clinical Laboratories). The reference range was 4.4-6.1%. Growth hormone/IGF-I axis
- Plasma levels of GH, IGF-I, free IGF-I, IGF-II, IGFBP- 1, IGFBP-2, and IGFBP-3 were measured Plasma IGF-I levels were obtained before and every 30 minutes for three hours following study drug administration on day 1 of treatment and 2-4 hours following study drug administration on days 7, 14, 21 , and 28 of treatment
- Total plasma IGF-I concentration were determined by radioimmunoassay (RIA) following acid ethanol extraction as described by Lieberman et al , supra Free IGF-I in plasma was separated from IGF- 1 complexed to binding protein using size-exclusion HPLC (SE-HPLC) with a TSK G2000SW column and a mobile phase of 0 2M sodium phosphate, 0 5% Tween-20 at pH 6 5
- SE-HPLC size-exclusion HPLC
- Measurement of IGF-1 levels after chromatography reveals IGF-I concentrations (extraction + RIA) of 7 0% and 19% Free IGF-1 concentration (SE-HPLC + RIA
- hypoglycemia was defined by a BG level equal to or lower than 50 mg/dL with or without symptomatology This definition of hypoglycemia was used for purposes of statistical analysis Subject Discontinuations
- the average daily BG levels during the last ten days of lead-in period (day - 19 to -28) compared to the average BG values during the last ten days of treatment (day 19 to 28) are shown in Table IV.
- the overall improvement in glycemic control observed in the rhIGF-I group wa due to lower glucose values prior to breakfast, lunch, and bedtime compared to the placebo group.
- Figure 15 shows the total IGF-I levels during the pharmacokinetics study on day 1 of treatment and 2-4 hours following study drug administration on day 7, 14, 21, and 28 of the treatment period.
- Average IGF-I levels in the placebo group fluctuated between 150 and 200 ng/mL (19.6-26 nmol/L) throughout the course of the study.
- low baseline IGF-I level (137+51 ng/mL; 17.9+6.7 nmol/L) rose to the mid-normal range (315+72 ng/mL; 41.2+9.4 nmol/L) by two hours following the first rhIGF-I injection.
- the IGF-I remained in the mid-normal range (340-440 ng/mL; 44-57 nmol/L) throughout the treatment period.
- Free IGF-I levels also rose following treatment, as shown in Figure 16.
- the average free IGF-1 level measured 2-4 hours after rhIGF-I injection was high on day 1 and remained elevated throughout the study. All values in the rhlGF-I-treated group were higher than those observed in the corresponding Tanner stage Placebo group (p ⁇ 0.01).
- the free IGF-I levels observed in the rhIGF-I group were similar to those measured in a group of healthy euthyroid controls (mean+SD), including 20 pre-pubertal controls (1 1.4+10.3 ng/mL) and 19 adolescents in Tanner stage 2-4 (14.5+12.3 ng/mL).
- rhIGF-I decreased triglycerides and the ratio of total cholesterol to high-density lipoprotein (HDL) cholesterol, as reported by Guler et al, Acta Paediatr. Scand.. 367. supra.
- the lipid profiles were in or near the normal range for most of the subjects prior to entering the trial (day 1 mean cholesterol 172 ⁇ 32 mg/kL or 4.5+0.8 mmolL).
- the lipid-improving effects of rhIGF-I may be better demonstrated in patients with more substantial abnormalities before treatment or through different dose levels or regimens.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SI9730204T SI0918536T1 (en) | 1996-08-13 | 1997-07-31 | Composition comprising insulin and insulin-like growth factor-i (igf-i) |
AU38243/97A AU731745B2 (en) | 1996-08-13 | 1997-07-31 | Composition comprising insulin and insulin-like growth factor-I (IGF-I) |
DE69706872T DE69706872T2 (en) | 1996-08-13 | 1997-07-31 | COMPILATIONS CONTAINING INSULIN AND THE INSULIN-LIKE GROWTH FACTOR-I (IGF-I) |
DK97935259T DK0918536T3 (en) | 1996-08-13 | 1997-07-31 | Composition comprising insulin and insulin-like growth factor-I (IGF-I) |
EP97935259A EP0918536B1 (en) | 1996-08-13 | 1997-07-31 | Composition comprising insulin and insulin-like growth factor-i (igf-i) |
JP50979998A JP4187075B2 (en) | 1996-08-13 | 1997-07-31 | Formulation |
IL128128A IL128128A (en) | 1996-08-13 | 1997-07-31 | Composition comprising insulin and insulin-like growth factor (i-igf) |
AT97935259T ATE205722T1 (en) | 1996-08-13 | 1997-07-31 | COMPOSITIONS CONTAINING INSULIN AND INSULIN-EQUAL GROWTH FACTOR-I (IGF-I). |
CA002261799A CA2261799C (en) | 1996-08-13 | 1997-07-31 | Composition comprising insulin and insulin-like growth factor-i (igf-i) |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/696,314 | 1996-08-13 | ||
US08/696,314 US5783556A (en) | 1996-08-13 | 1996-08-13 | Formulated insulin-containing composition |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998006423A1 true WO1998006423A1 (en) | 1998-02-19 |
Family
ID=24796556
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1997/013566 WO1998006423A1 (en) | 1996-08-13 | 1997-07-31 | Composition comprising insulin and insulin-like growth factor-i (igf-i) |
Country Status (16)
Country | Link |
---|---|
US (1) | US5783556A (en) |
EP (2) | EP1114644B1 (en) |
JP (1) | JP4187075B2 (en) |
AR (1) | AR009066A1 (en) |
AT (2) | ATE205722T1 (en) |
AU (1) | AU731745B2 (en) |
CA (1) | CA2261799C (en) |
DE (2) | DE69706872T2 (en) |
DK (2) | DK0918536T3 (en) |
ES (2) | ES2162321T3 (en) |
HK (1) | HK1042229B (en) |
IL (1) | IL128128A (en) |
PT (2) | PT1114644E (en) |
SI (1) | SI1114644T1 (en) |
WO (1) | WO1998006423A1 (en) |
ZA (1) | ZA976598B (en) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999062536A2 (en) * | 1998-06-01 | 1999-12-09 | Celtrix Pharmaceuticals, Inc. | Pharmaceutical formulations for igf/igfbp |
WO2000061177A1 (en) * | 1999-04-08 | 2000-10-19 | Genentech, Inc. | Composition based on oppositely-charged polypeptides |
WO2010089706A1 (en) | 2009-02-04 | 2010-08-12 | Ecole Polytechnique Federale De Lausanne (Epfl) | Use of igf-1 and nt-3 in the treatment of x-linked adrenoleukodystrophy |
WO2014102623A1 (en) * | 2012-12-26 | 2014-07-03 | Wockhardt Limited | Pharmaceutical composition |
US8968198B2 (en) | 2006-02-22 | 2015-03-03 | Dexcom, Inc. | Analyte sensor |
US9247900B2 (en) | 2004-07-13 | 2016-02-02 | Dexcom, Inc. | Analyte sensor |
US9357951B2 (en) | 2009-09-30 | 2016-06-07 | Dexcom, Inc. | Transcutaneous analyte sensor |
US9414777B2 (en) | 2004-07-13 | 2016-08-16 | Dexcom, Inc. | Transcutaneous analyte sensor |
US9986942B2 (en) | 2004-07-13 | 2018-06-05 | Dexcom, Inc. | Analyte sensor |
US10610137B2 (en) | 2005-03-10 | 2020-04-07 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
WO2023025914A1 (en) * | 2021-08-26 | 2023-03-02 | Forschungsinstitut für Nutztierbiologie | Compositions comprising igf-1, igfbp-2 and insulin, and use thereof |
Families Citing this family (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6428771B1 (en) | 1995-05-15 | 2002-08-06 | Pharmaceutical Discovery Corporation | Method for drug delivery to the pulmonary system |
US7312196B2 (en) * | 1997-01-08 | 2007-12-25 | Amylin Pharmaceuticals, Inc. | Formulations for amylin agonist peptides |
US6410511B2 (en) * | 1997-01-08 | 2002-06-25 | Amylin Pharmaceuticals, Inc. | Formulations for amylin agonist peptides |
AU718500B2 (en) * | 1997-01-23 | 2000-04-13 | Sumitomo Pharmaceuticals Company, Limited | Remedies for diabetes |
EP1006794B1 (en) * | 1997-03-12 | 2007-11-28 | Robert W. Esmond | A method for treating or preventing alzheimer's disease |
CA2319195A1 (en) | 1998-02-02 | 1999-08-05 | Trustees Of Tufts College | Method of regulating glucose metabolism, and reagents related thereto |
US20040058873A1 (en) * | 1998-03-12 | 2004-03-25 | Esmond Robert W. | Method for treating or preventing Alzheimer's disease |
AU3473999A (en) * | 1998-04-03 | 1999-10-25 | Chiron Corporation | Injectable igf-formulations containing succinate as buffering agent |
US6211144B1 (en) * | 1998-10-16 | 2001-04-03 | Novo Nordisk A/S | Stable concentrated insulin preparations for pulmonary delivery |
WO2001000223A2 (en) * | 1999-06-25 | 2001-01-04 | Minimed Inc. | Multiple agent diabetes therapy |
US9006175B2 (en) | 1999-06-29 | 2015-04-14 | Mannkind Corporation | Potentiation of glucose elimination |
PT1196430E (en) | 1999-06-29 | 2012-04-18 | Mannkind Corp | Purification and stabilization of peptide and protein pharmaceutical agents |
US7651703B2 (en) * | 1999-10-15 | 2010-01-26 | Genentech, Inc. | Injection vehicle for polymer-based formulations |
US7582311B1 (en) | 1999-10-15 | 2009-09-01 | Genentech, Inc. | Injection vehicle for polymer-based formulations |
WO2002067969A2 (en) | 2001-02-21 | 2002-09-06 | Medtronic Minimed, Inc. | Stabilized insulin formulations |
DE10114178A1 (en) * | 2001-03-23 | 2002-10-10 | Aventis Pharma Gmbh | Zinc-free and low-zinc insulin preparations with improved stability |
GB0113179D0 (en) * | 2001-05-31 | 2001-07-25 | Novartis Ag | Organic compounds |
SE0101980D0 (en) * | 2001-06-01 | 2001-06-01 | Astrazeneca Ab | Pharmaceutical combination |
SE0101982D0 (en) * | 2001-06-01 | 2001-06-01 | Astrazeneca Ab | Pharmaceutical combination |
FR2826278B1 (en) * | 2001-06-20 | 2005-03-25 | Lipha | USE OF ANTIDIABETIC AGENTS FOR MANUFACTURING A MEDICAMENT HAVING A HEALING EFFECT |
US6737401B2 (en) * | 2001-06-28 | 2004-05-18 | Metronic Minimed, Inc. | Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom |
EP2316470A3 (en) * | 2001-11-26 | 2011-08-24 | Trustees Of Tufts College | Peptidomimetic inhibitors of post-proline cleaving enzymes |
WO2003045228A2 (en) * | 2001-11-26 | 2003-06-05 | Trustees Of Tufts College | Methods for treating autoimmune disorders, and reagents related thereto |
WO2003080149A2 (en) | 2002-03-20 | 2003-10-02 | Mannkind Corporation | Inhalation apparatus |
DE10227232A1 (en) * | 2002-06-18 | 2004-01-15 | Aventis Pharma Deutschland Gmbh | Sour insulin preparations with improved stability |
AU2003303646B2 (en) | 2002-12-31 | 2010-03-04 | Altus Pharmaceuticals Inc. | Human growth hormone crystals and methods for preparing them |
WO2004078198A1 (en) * | 2003-03-04 | 2004-09-16 | The Technology Development Company Ltd. | Long acting injectable insulin composition and methods of making and using thereof |
US20080090753A1 (en) * | 2004-03-12 | 2008-04-17 | Biodel, Inc. | Rapid Acting Injectable Insulin Compositions |
US20080096800A1 (en) * | 2004-03-12 | 2008-04-24 | Biodel, Inc. | Rapid mucosal gel or film insulin compositions |
AU2005222613B2 (en) * | 2004-03-12 | 2009-12-17 | Biodel, Inc. | Rapid acting drug delivery compositions |
DE602005024413D1 (en) | 2004-08-20 | 2010-12-09 | Mannkind Corp | CATALYSIS OF DIKETOPIPERAZINE SYNTHESIS |
ES2540886T3 (en) | 2004-08-23 | 2015-07-14 | Mannkind Corporation | Dicetopiperazine salts for drug administration |
US20090060861A1 (en) * | 2005-05-25 | 2009-03-05 | Novo Nordisk A/S | Stabilized Polypeptide Formulations |
CN101180081B (en) * | 2005-05-25 | 2015-08-26 | 诺沃-诺迪斯克有限公司 | Stable polypeptide formulations |
KR101557502B1 (en) | 2005-09-14 | 2015-10-06 | 맨카인드 코포레이션 | Method of drug formulation based on increasing the affinity of active agents for crystalline micropaticle surfaces |
US8084420B2 (en) | 2005-09-29 | 2011-12-27 | Biodel Inc. | Rapid acting and long acting insulin combination formulations |
US7713929B2 (en) | 2006-04-12 | 2010-05-11 | Biodel Inc. | Rapid acting and long acting insulin combination formulations |
US20070086952A1 (en) * | 2005-09-29 | 2007-04-19 | Biodel, Inc. | Rapid Acting and Prolonged Acting Inhalable Insulin Preparations |
AU2007216966C1 (en) | 2006-02-22 | 2014-03-20 | Mannkind Corporation | A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent |
CA2649109A1 (en) | 2006-04-12 | 2007-10-25 | Biodel, Inc. | Rapid acting and long acting insulin combination formulations |
US20090147006A1 (en) * | 2007-12-07 | 2009-06-11 | Roche Diagnostics Operations, Inc. | Method and system for event based data comparison |
FR2925333B1 (en) * | 2007-12-19 | 2012-04-13 | Farid Bennis | PHARMACEUTICAL COMPOSITIONS COMPRISING AT LEAST ONE PROTEIN ACTIVE INGREDIENT PROTECTS DIGESTIVE ENZYMES |
AU2009204309B2 (en) * | 2008-01-04 | 2012-11-22 | Biodel, Inc. | Insulin formulations for insulin release as a function of tissue glucose levels |
TWI394580B (en) * | 2008-04-28 | 2013-05-01 | Halozyme Inc | Super fast-acting insulin compositions |
PL2293833T3 (en) | 2008-06-13 | 2016-08-31 | Mannkind Corp | A dry powder inhaler and system for drug delivery |
US8485180B2 (en) | 2008-06-13 | 2013-07-16 | Mannkind Corporation | Dry powder drug delivery system |
EP2609954B1 (en) | 2008-06-20 | 2021-12-29 | MannKind Corporation | An interactive apparatus for real-time profiling of inhalation efforts |
TWI532497B (en) | 2008-08-11 | 2016-05-11 | 曼凱公司 | Use of ultrarapid acting insulin |
DK2349324T3 (en) | 2008-10-17 | 2017-12-11 | Sanofi Aventis Deutschland | COMBINATION OF AN INSULIN AND A GLP-1 AGONIST |
US8314106B2 (en) | 2008-12-29 | 2012-11-20 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
US9060927B2 (en) * | 2009-03-03 | 2015-06-23 | Biodel Inc. | Insulin formulations for rapid uptake |
EP2405963B1 (en) | 2009-03-11 | 2013-11-06 | MannKind Corporation | Apparatus, system and method for measuring resistance of an inhaler |
KR20180079458A (en) | 2009-06-12 | 2018-07-10 | 맨카인드 코포레이션 | Diketopiperazine microparticles with defined specific surface areas |
US9016147B2 (en) | 2009-11-03 | 2015-04-28 | Mannkind Corporation | Apparatus and method for simulating inhalation efforts |
JP5973918B2 (en) | 2009-11-13 | 2016-08-23 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Pharmaceutical composition comprising a GLP-1 agonist and methionine |
KR101836070B1 (en) | 2009-11-13 | 2018-03-09 | 사노피-아벤티스 도이칠란트 게엠베하 | Pharmaceutical composition comprising a glp-1 agonist, an insulin, and methionine |
CA2801936C (en) | 2010-06-21 | 2021-06-01 | Mannkind Corporation | Dry powder drug delivery system and methods |
PT2611458T (en) | 2010-08-30 | 2016-12-16 | Sanofi Aventis Deutschland | Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2 |
EP2694402B1 (en) | 2011-04-01 | 2017-03-22 | MannKind Corporation | Blister package for pharmaceutical cartridges |
US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
WO2012174472A1 (en) | 2011-06-17 | 2012-12-20 | Mannkind Corporation | High capacity diketopiperazine microparticles |
US9993529B2 (en) | 2011-06-17 | 2018-06-12 | Halozyme, Inc. | Stable formulations of a hyaluronan-degrading enzyme |
CN108079281A (en) | 2011-08-29 | 2018-05-29 | 赛诺菲-安万特德国有限公司 | For the pharmaceutical composition of the glycemic control in diabetes B patient |
AR087744A1 (en) | 2011-09-01 | 2014-04-16 | Sanofi Aventis Deutschland | PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OF A NEURODEGENERATIVE DISEASE |
EP2776053A1 (en) | 2011-10-24 | 2014-09-17 | MannKind Corporation | Methods and compositions for treating pain |
AU2013289957B2 (en) | 2012-07-12 | 2017-02-23 | Mannkind Corporation | Dry powder drug delivery systems and methods |
AR091902A1 (en) * | 2012-07-25 | 2015-03-11 | Hanmi Pharm Ind Co Ltd | LIQUID FORMULATION OF A PROLONGED INSULIN CONJUGATE |
EP2911690A1 (en) | 2012-10-26 | 2015-09-02 | MannKind Corporation | Inhalable influenza vaccine compositions and methods |
KR102499439B1 (en) | 2013-03-15 | 2023-02-13 | 맨카인드 코포레이션 | Microcrystalline diketopiperazine compositions and methods |
MX2020009878A (en) | 2013-07-18 | 2022-07-27 | Mannkind Corp | Heat-stable dry powder pharmaceutical compositions and methods. |
JP2016530930A (en) | 2013-08-05 | 2016-10-06 | マンカインド コーポレイション | Ventilation device and method |
SG11201604710XA (en) | 2014-01-09 | 2016-07-28 | Sanofi Sa | Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives |
CN105899191B (en) * | 2014-01-09 | 2020-06-16 | 赛诺菲 | Stabilized glycerol-free pharmaceutical formulations of insulin analogues and/or insulin derivatives |
US10307464B2 (en) | 2014-03-28 | 2019-06-04 | Mannkind Corporation | Use of ultrarapid acting insulin |
US10561806B2 (en) | 2014-10-02 | 2020-02-18 | Mannkind Corporation | Mouthpiece cover for an inhaler |
CN107206058A (en) | 2014-12-12 | 2017-09-26 | 赛诺菲-安万特德国有限公司 | Insulin glargine/lixisenatide fixed ratio preparaton |
TWI748945B (en) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | Treatment type 2 diabetes mellitus patients |
TW201705975A (en) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | Treatment of type 2 diabetes mellitus patients |
EP4228676A1 (en) * | 2020-10-19 | 2023-08-23 | Oak Hill Bio Limited | Compositions suitable for use in neonates |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0331630A1 (en) * | 1988-02-05 | 1989-09-06 | Ciba-Geigy Ag | Use of IGF-I for the manufacture of a preparation for treating and preventing secondary effects of hyperinsulinemia in diabetics treated with insulin |
WO1996001125A1 (en) * | 1994-07-01 | 1996-01-18 | Pharmacia & Upjohn Ab | Use of insulin and igf-i |
WO1996002270A1 (en) * | 1994-07-13 | 1996-02-01 | Gropep Pty. Ltd. | Use of insulin-like growth factor in combination with insulin |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE95236T1 (en) * | 1983-04-25 | 1993-10-15 | Chiron Corp | HYBRID DNA SYNTHESIS OF MATURE INSULIN-LIKE GROWTH FACTORS. |
IL71991A (en) * | 1983-06-06 | 1994-05-30 | Genentech Inc | Preparation of mature human IGF and EGF via prokaryotic recombinant DNA technology |
US5091173A (en) * | 1989-06-29 | 1992-02-25 | The University Of Dundee | Hair growth composition |
GB8920381D0 (en) * | 1989-09-08 | 1989-10-25 | Greater Glasgow Health Board | Treatment of insulin-resistant diabetes |
JPH0818999B2 (en) * | 1990-01-05 | 1996-02-28 | 藤沢薬品工業株式会社 | Insulin-like growth factor I dry formulation |
US5126324A (en) * | 1990-06-07 | 1992-06-30 | Genentech, Inc. | Method of enhancing growth in patients using combination therapy |
DK0586589T3 (en) * | 1991-05-24 | 1997-09-22 | Amylin Pharmaceuticals Inc | Amylin or amylin analogue, possibly containing insulin, for the treatment of anorexia and related conditions |
US5202119A (en) * | 1991-06-28 | 1993-04-13 | Genentech, Inc. | Method of stimulating immune response |
JPH0543453A (en) * | 1991-08-20 | 1993-02-23 | Sumitomo Pharmaceut Co Ltd | Local sustained-release preparation for accelerating wound curing |
HUT67319A (en) * | 1991-08-30 | 1995-03-28 | Life Medical Sciences Inc | Compositions for treating wounds |
CA2123685C (en) * | 1991-11-25 | 2003-10-07 | Hans-Arne Hansson | Medicament for promoting growth of mammalian nerve |
DE4208552A1 (en) * | 1992-03-17 | 1993-09-23 | Liedtke Pharmed Gmbh | TOPICAL MEDICINE FORMS WITH INSULIN |
SE9201573D0 (en) * | 1992-05-19 | 1992-05-19 | Kabi Pharmacia Ab | USE OF IGF-1 |
AU674527B2 (en) * | 1992-06-24 | 1997-01-02 | Hot Pepper Wax, Inc. | Organic pesticide |
WO1994004030A1 (en) * | 1992-08-26 | 1994-03-03 | Celtrix Pharmaceuticals, Inc. | Method for systemic treatment of catabolic conditions and systemic tissue injury |
JPH08500123A (en) * | 1993-01-25 | 1996-01-09 | ザ ベス イスラエル ホスピタル アソシエイション | Method for modifying barrier properties of IGF-I sensitive cells, diagnostic method and screening method |
AU6093794A (en) * | 1993-01-29 | 1994-08-15 | Synergen, Inc. | Wound healing composition |
SE9402119D0 (en) * | 1994-06-16 | 1994-06-16 | Pharmacia Ab | Solution |
SE9402370D0 (en) * | 1994-07-04 | 1994-07-04 | Pharmacia Ab | Use of IGF-I |
DK1044015T3 (en) * | 1998-01-09 | 2008-12-08 | Amylin Pharmaceuticals Inc | Formulations with amylin agonist peptides and insulin |
ATE277630T1 (en) * | 1998-10-16 | 2004-10-15 | Novo Nordisk As | STABLE CONCENTRATED INSULIN PREPARATIONS FOR PULMONARY ADMINISTRATION |
CA2369451C (en) * | 1999-04-08 | 2009-09-22 | Genentech, Inc. | Composition based on oppositely-charged polypeptides |
WO2001000223A2 (en) * | 1999-06-25 | 2001-01-04 | Minimed Inc. | Multiple agent diabetes therapy |
-
1996
- 1996-08-13 US US08/696,314 patent/US5783556A/en not_active Expired - Lifetime
-
1997
- 1997-07-24 ZA ZA976598A patent/ZA976598B/en unknown
- 1997-07-31 AT AT97935259T patent/ATE205722T1/en active
- 1997-07-31 AT AT01106315T patent/ATE222120T1/en active
- 1997-07-31 PT PT01106315T patent/PT1114644E/en unknown
- 1997-07-31 WO PCT/US1997/013566 patent/WO1998006423A1/en active IP Right Grant
- 1997-07-31 DK DK97935259T patent/DK0918536T3/en active
- 1997-07-31 PT PT97935259T patent/PT918536E/en unknown
- 1997-07-31 ES ES97935259T patent/ES2162321T3/en not_active Expired - Lifetime
- 1997-07-31 AU AU38243/97A patent/AU731745B2/en not_active Expired
- 1997-07-31 DE DE69706872T patent/DE69706872T2/en not_active Expired - Lifetime
- 1997-07-31 EP EP01106315A patent/EP1114644B1/en not_active Expired - Lifetime
- 1997-07-31 ES ES01106315T patent/ES2180523T3/en not_active Expired - Lifetime
- 1997-07-31 IL IL128128A patent/IL128128A/en not_active IP Right Cessation
- 1997-07-31 JP JP50979998A patent/JP4187075B2/en not_active Expired - Lifetime
- 1997-07-31 DK DK01106315T patent/DK1114644T3/en active
- 1997-07-31 CA CA002261799A patent/CA2261799C/en not_active Expired - Lifetime
- 1997-07-31 SI SI9730387T patent/SI1114644T1/en unknown
- 1997-07-31 DE DE69714796T patent/DE69714796T2/en not_active Expired - Lifetime
- 1997-07-31 EP EP97935259A patent/EP0918536B1/en not_active Expired - Lifetime
- 1997-08-12 AR ARP970103667A patent/AR009066A1/en active IP Right Grant
-
2002
- 2002-01-10 HK HK02100191.5A patent/HK1042229B/en not_active IP Right Cessation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0331630A1 (en) * | 1988-02-05 | 1989-09-06 | Ciba-Geigy Ag | Use of IGF-I for the manufacture of a preparation for treating and preventing secondary effects of hyperinsulinemia in diabetics treated with insulin |
WO1996001125A1 (en) * | 1994-07-01 | 1996-01-18 | Pharmacia & Upjohn Ab | Use of insulin and igf-i |
WO1996002270A1 (en) * | 1994-07-13 | 1996-02-01 | Gropep Pty. Ltd. | Use of insulin-like growth factor in combination with insulin |
Non-Patent Citations (4)
Title |
---|
JABRI N. ET AL: "Adverse effects of recombinant human insulin-like growth factor I in obese insulin-resistant type II diabetic patients", DIABETES, 1994, 43/3 (369-374), USA, XP002045793 * |
QUATTRIN T. ET AL: "Dual hormonal replacement with insulin and recombinant human insulin- like growth factor I in IDDM: Effects on glycemic control, IGF-I levels, and safety profile", DIABETES CARE, 1997, 20/3 (374-380), USA, XP002045791 * |
THRAILKILL K. ET AL: "Dual hormonal replacement therapy with insulin and recombinant human insulin-like growth factor (IGF)-I in insulin-dependent diabetes mellitus: Effects on the growth hormone/IGF/IGF-binding protein system", JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, 1997, 82/4 (1181-1187), USA, XP002045795 * |
VON WERDER K.: "Treatment of insulin-resistant diabetes mellitus with a recombinant compound: Comment", FORTSCHR. MED., 1992, 110/31 (10-11), GERMANY, XP002045794 * |
Cited By (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999062536A2 (en) * | 1998-06-01 | 1999-12-09 | Celtrix Pharmaceuticals, Inc. | Pharmaceutical formulations for igf/igfbp |
WO1999062536A3 (en) * | 1998-06-01 | 2000-03-30 | Celtrix Pharma | Pharmaceutical formulations for igf/igfbp |
US6436897B2 (en) | 1998-06-01 | 2002-08-20 | Celtrix Pharmaceuticals, Inc. | Pharmaceutical formulations for IGF/IGFBP |
WO2000061177A1 (en) * | 1999-04-08 | 2000-10-19 | Genentech, Inc. | Composition based on oppositely-charged polypeptides |
US6559122B1 (en) | 1999-04-08 | 2003-05-06 | Genentech, Inc. | Formulated composition |
US7186686B2 (en) | 1999-04-08 | 2007-03-06 | Genentech, Inc. | Formulated composition |
US10799159B2 (en) | 2004-07-13 | 2020-10-13 | Dexcom, Inc. | Analyte sensor |
US10827956B2 (en) | 2004-07-13 | 2020-11-10 | Dexcom, Inc. | Analyte sensor |
US10799158B2 (en) | 2004-07-13 | 2020-10-13 | Dexcom, Inc. | Analyte sensor |
US9247900B2 (en) | 2004-07-13 | 2016-02-02 | Dexcom, Inc. | Analyte sensor |
US10813576B2 (en) | 2004-07-13 | 2020-10-27 | Dexcom, Inc. | Analyte sensor |
US9414777B2 (en) | 2004-07-13 | 2016-08-16 | Dexcom, Inc. | Transcutaneous analyte sensor |
US9668677B2 (en) | 2004-07-13 | 2017-06-06 | Dexcom, Inc. | Analyte sensor |
US11883164B2 (en) | 2004-07-13 | 2024-01-30 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US9814414B2 (en) | 2004-07-13 | 2017-11-14 | Dexcom, Inc. | Transcutaneous analyte sensor |
US9986942B2 (en) | 2004-07-13 | 2018-06-05 | Dexcom, Inc. | Analyte sensor |
US10314525B2 (en) | 2004-07-13 | 2019-06-11 | Dexcom, Inc. | Analyte sensor |
US10524703B2 (en) | 2004-07-13 | 2020-01-07 | Dexcom, Inc. | Transcutaneous analyte sensor |
US11064917B2 (en) | 2004-07-13 | 2021-07-20 | Dexcom, Inc. | Analyte sensor |
US11045120B2 (en) | 2004-07-13 | 2021-06-29 | Dexcom, Inc. | Analyte sensor |
US11026605B1 (en) | 2004-07-13 | 2021-06-08 | Dexcom, Inc. | Analyte sensor |
US10993642B2 (en) | 2004-07-13 | 2021-05-04 | Dexcom, Inc. | Analyte sensor |
US10993641B2 (en) | 2004-07-13 | 2021-05-04 | Dexcom, Inc. | Analyte sensor |
US10709362B2 (en) | 2004-07-13 | 2020-07-14 | Dexcom, Inc. | Analyte sensor |
US10709363B2 (en) | 2004-07-13 | 2020-07-14 | Dexcom, Inc. | Analyte sensor |
US10980452B2 (en) | 2004-07-13 | 2021-04-20 | Dexcom, Inc. | Analyte sensor |
US10932700B2 (en) | 2004-07-13 | 2021-03-02 | Dexcom, Inc. | Analyte sensor |
US10722152B2 (en) | 2004-07-13 | 2020-07-28 | Dexcom, Inc. | Analyte sensor |
US10918314B2 (en) | 2004-07-13 | 2021-02-16 | Dexcom, Inc. | Analyte sensor |
US10918313B2 (en) | 2004-07-13 | 2021-02-16 | Dexcom, Inc. | Analyte sensor |
US10918315B2 (en) | 2004-07-13 | 2021-02-16 | Dexcom, Inc. | Analyte sensor |
US10925524B2 (en) | 2005-03-10 | 2021-02-23 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10716498B2 (en) | 2005-03-10 | 2020-07-21 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10610137B2 (en) | 2005-03-10 | 2020-04-07 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US11051726B2 (en) | 2005-03-10 | 2021-07-06 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10856787B2 (en) | 2005-03-10 | 2020-12-08 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10898114B2 (en) | 2005-03-10 | 2021-01-26 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10610135B2 (en) | 2005-03-10 | 2020-04-07 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10918317B2 (en) | 2005-03-10 | 2021-02-16 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10918316B2 (en) | 2005-03-10 | 2021-02-16 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10610136B2 (en) | 2005-03-10 | 2020-04-07 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10743801B2 (en) | 2005-03-10 | 2020-08-18 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10918318B2 (en) | 2005-03-10 | 2021-02-16 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US11000213B2 (en) | 2005-03-10 | 2021-05-11 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10617336B2 (en) | 2005-03-10 | 2020-04-14 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10709364B2 (en) | 2005-03-10 | 2020-07-14 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10813577B2 (en) | 2005-06-21 | 2020-10-27 | Dexcom, Inc. | Analyte sensor |
US8968198B2 (en) | 2006-02-22 | 2015-03-03 | Dexcom, Inc. | Analyte sensor |
US9724028B2 (en) | 2006-02-22 | 2017-08-08 | Dexcom, Inc. | Analyte sensor |
WO2010089706A1 (en) | 2009-02-04 | 2010-08-12 | Ecole Polytechnique Federale De Lausanne (Epfl) | Use of igf-1 and nt-3 in the treatment of x-linked adrenoleukodystrophy |
US10667733B2 (en) | 2009-09-30 | 2020-06-02 | Dexcom, Inc. | Transcutaneous analyte sensor |
US10835161B2 (en) | 2009-09-30 | 2020-11-17 | Dexcom, Inc. | Transcutaneous analyte sensor |
US9357951B2 (en) | 2009-09-30 | 2016-06-07 | Dexcom, Inc. | Transcutaneous analyte sensor |
US11937927B2 (en) | 2009-09-30 | 2024-03-26 | Dexcom, Inc. | Transcutaneous analyte sensor |
WO2014102623A1 (en) * | 2012-12-26 | 2014-07-03 | Wockhardt Limited | Pharmaceutical composition |
WO2023025914A1 (en) * | 2021-08-26 | 2023-03-02 | Forschungsinstitut für Nutztierbiologie | Compositions comprising igf-1, igfbp-2 and insulin, and use thereof |
Also Published As
Publication number | Publication date |
---|---|
DE69714796T2 (en) | 2003-04-03 |
EP0918536B1 (en) | 2001-09-19 |
US5783556A (en) | 1998-07-21 |
PT1114644E (en) | 2002-12-31 |
AU3824397A (en) | 1998-03-06 |
ATE222120T1 (en) | 2002-08-15 |
CA2261799C (en) | 2009-09-08 |
DE69714796D1 (en) | 2002-09-19 |
DK0918536T3 (en) | 2001-12-03 |
HK1042229B (en) | 2003-08-15 |
PT918536E (en) | 2002-03-28 |
DK1114644T3 (en) | 2002-11-04 |
JP4187075B2 (en) | 2008-11-26 |
DE69706872D1 (en) | 2001-10-25 |
EP1114644A1 (en) | 2001-07-11 |
HK1042229A1 (en) | 2002-08-09 |
JP2000516229A (en) | 2000-12-05 |
AR009066A1 (en) | 2000-03-08 |
EP1114644B1 (en) | 2002-08-14 |
CA2261799A1 (en) | 1998-02-19 |
ATE205722T1 (en) | 2001-10-15 |
ES2180523T3 (en) | 2003-02-16 |
DE69706872T2 (en) | 2002-04-25 |
EP0918536A1 (en) | 1999-06-02 |
IL128128A (en) | 2007-06-17 |
SI1114644T1 (en) | 2002-12-31 |
ES2162321T3 (en) | 2001-12-16 |
AU731745B2 (en) | 2001-04-05 |
ZA976598B (en) | 1999-02-17 |
IL128128A0 (en) | 1999-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0918536B1 (en) | Composition comprising insulin and insulin-like growth factor-i (igf-i) | |
US5374620A (en) | Growth-promoting composition and its use | |
US6410511B2 (en) | Formulations for amylin agonist peptides | |
US5597802A (en) | Method of formulating IGF-I with growth hormone | |
US7312196B2 (en) | Formulations for amylin agonist peptides | |
EP1165119B1 (en) | Composition based on oppositely-charged polypeptides | |
EP1044015B1 (en) | Formulations for amylin agonist peptides with insulin | |
US5741776A (en) | Method of administration of IGF-I | |
US5565428A (en) | Method of administration of IGF-I | |
AU752411B2 (en) | Formulation | |
NZ539505A (en) | Method of administration of IGF-I |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2261799 Country of ref document: CA Ref country code: CA Ref document number: 2261799 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/1999/001425 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 1998 509799 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1997935259 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1997935259 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 1997935259 Country of ref document: EP |